Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches.
Paola ParentePietro ParcesepeClaudia CovelliNunzio OlivieriAndrea RemoMassimo PancioneTiziana Pia LatianoPaolo GrazianoEvaristo MaielloGuido GiordanoPublished in: Gastroenterology research and practice (2018)
Pancreatic ductal adenocarcinoma is a lethal disease for which radical surgery and chemotherapy represent the only curative options for a small proportion of patients. Recently, FOLFIRINOX and nab-paclitaxel plus gemcitabine have improved the survival of metastatic patients but prognosis remains poor. A pancreatic tumor microenvironment is a dynamic milieu of cellular and acellular elements, and it represents one of the major limitations to chemotherapy efficacy. The continued crosstalk between cancer cells and the surrounding microenvironment causes immunosuppression within pancreatic immune infiltrate increasing tumor aggressiveness. Several potential targets have been identified among tumor microenvironment components, and different therapeutic approaches are under investigation. In this article, we provide a qualitative literature review about the crosstalk between the tumor microenvironment components and immune system in pancreatic cancer. Finally, we discuss potential therapeutic strategies targeting the tumor microenvironment and we show the ongoing trials.
Keyphrases
- end stage renal disease
- locally advanced
- newly diagnosed
- ejection fraction
- prognostic factors
- chronic kidney disease
- squamous cell carcinoma
- small cell lung cancer
- minimally invasive
- peritoneal dialysis
- stem cells
- rectal cancer
- radiation therapy
- human health
- drug delivery
- risk assessment
- coronary artery disease
- percutaneous coronary intervention
- cancer therapy
- acute coronary syndrome
- advanced non small cell lung cancer
- chemotherapy induced
- patient reported
- tyrosine kinase